Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The vast majority of persons living with HIV-1 who discontinue antiretroviral therapy (ART) demonstrate viral rebound, but the tissue-level events that lead to rebound viremia are poorly understood. Here we report the origin, dynamics, and correlates of viral rebound in 16 rhesus macaques (RMs) infected with molecularly barcoded SIVmac239M, treated with ART for 70 weeks, and necropsied on day 12 after ART discontinuation. Barcode analysis of plasma following ART discontinuation identified 1 to 38 rebounding barcode-defined viral lineages per animal, with 1 to 4 rebounding lineages contributing to first measurable rebound viremia. Analysis of barcode viral RNA (vRNA) expression in necropsy tissues revealed presumptive anatomic origin sites for 56 of 175 total rebounding viral lineages, with significant enrichment in the gastrointestinal (GI) tract and GI-associated lymph nodes. Daily transcriptomic and proteomic profiling in peripheral blood following ART discontinuation showed upregulation of pathways related to T cell signaling, cytokine responses, and cellular metabolism prior to detectable rebound viremia. These data suggest that viral rebound following ART discontinuation is initiated by local tissue replication of a limited number of clonal lineages, followed by systemic expansion of the initial rebounding lineages and serial initiation of replication of multiple additional clonal lineages. These findings provide mechanistic insights into the processes that result in viral rebound following ART discontinuation and will contribute to next generation HIV-1 cure strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407973 | PMC |
| http://dx.doi.org/10.1101/2025.08.30.673277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Origin and Correlates of Viral Rebound in SIV-Infected Rhesus Macaques Following ART Discontinuation.
bioRxiv
August 2025
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
The vast majority of persons living with HIV-1 who discontinue antiretroviral therapy (ART) demonstrate viral rebound, but the tissue-level events that lead to rebound viremia are poorly understood. Here we report the origin, dynamics, and correlates of viral rebound in 16 rhesus macaques (RMs) infected with molecularly barcoded SIVmac239M, treated with ART for 70 weeks, and necropsied on day 12 after ART discontinuation. Barcode analysis of plasma following ART discontinuation identified 1 to 38 rebounding barcode-defined viral lineages per animal, with 1 to 4 rebounding lineages contributing to first measurable rebound viremia.
View Article and Find Full Text PDFNo changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial).
BMC Infect Dis
September 2025
Department of Infectious Diseases, Center of Clinical Research and Disruption of Infectious Diseases (CREDID), Copenhagen University Hospital - Amager and Hvidovre, Kettegaard Allé 30, Hvidovre, 2650, Denmark.
Background: Antiretroviral therapy (ART) in people with HIV (PWH) can lead to weight gain, but the effects of nucleoside reverse transcriptase inhibitors such as abacavir (ABC) are not well understood. In this study, we investigated whether discontinuing ABC would mitigate weight changes and metabolic complications in PWH.
Methods: In a randomized controlled trial including PWH on dolutegravir, ABC, and lamivudine (DTG/ABC/3TC), participants were randomized 2:1 to either switch to DTG/3TC or continue DTG/ABC/3TC.
[Recent advances in research of cure of HIV infection].
Rinsho Ketsueki
September 2025
Department of Hematology, Graduate School of Medicine, Kyoto University.
Antiretroviral therapy (ART) is a well-established treatment for HIV infection that suppresses viral replication by inhibiting viral enzymatic activity, thereby preventing progression to immunodeficiency. However, discontinuation of ART typically leads to rapid viral rebound within weeks, due to the reactivation of latent HIV from long-lived reservoirs such as resting CD4 T cells. Eradication of these latent reservoirs is essential to achieve a cure for HIV.
View Article and Find Full Text PDFSuppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort.
HIV Med
August 2025
Epividian, Raleigh, North Carolina, USA.
Objectives: To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed-dose combination 3-drug and 2-drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US.
Methods: From the OPERA cohort, ART-experienced, virologically suppressed (viral load <200 copies/mL) adults with HIV who switched to B/F/TAF or DTG/3TC (01AUG2020-30JUN2022) were followed through 31DEC2022, death, loss to follow-up or discontinuation. Cox proportional hazard models with stabilized inverse probability of treatment weights were used to assess the association between regimen and time to confirmed virologic failure (cVF; 2 viral loads ≥200 copies/mL or 1 viral load ≥200 copies/mL + discontinuation) or time to discontinuation.
The role of maintenance therapy and its cessation in patients with multiple myeloma.
Leuk Lymphoma
August 2025
Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Lenalidomide maintenance therapy remains a cornerstone of post-induction treatment in multiple myeloma (MM), supported by various landmark trials demonstrating improved outcomes with lenalidomide maintenance over observation or placebo following autologous stem cell transplant (ASCT). Despite advancements in the MM treatment landscape, including the integration of quadruplet induction therapies and measurable residual disease (MRD) assessment to define deep responses, most maintenance strategies continue to focus on maintenance intensification rather than de-escalation. With an increasing number of patients achieving sustained deep responses, the optimal application and duration of maintenance therapy deserve reevaluation.
View Article and Find Full Text PDF